Clinical Trial Update: Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating nivolumab with HF10 oncolytic viral therapy in resectable advanced melanoma was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HF10 oncolytic viral therapy (HF10)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Utah | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2019-10-10